Category: 50998-17-9

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.50998-17-9,6-Bromoquinoxaline,as a common compound, the synthetic route is as follows.

A solution of 6-bromo-quinoxaline (261 mg, 1.25 mmol), 1-ethoxyvinyltri-n-butyltin (0.47 mL, 1.4 mmol), palladium(II) acetate (16 mg) and tri-t-butylphosphonium tetrafluoroborate (41 mg) in anhydrous DMF (4 mL) under a nitrogen atmosphere was heated at 120 C. for 1 hr. The reaction mixture was cooled to ambient temperature and partitioned between ethyl acetate (25 mL) and H2O (10 mL). The organic extraction was washed with brine, dried (MgSO4), filtered, and concentrated. The concentrate was chromatographed on silica gel eluting with ethyl acetate:hexanes (1:1) to provide 110 mg of the title compound. 1H NMR (300 MHz, CDCl3) delta 2.79 (s, 3H), 8.18 (d, J=9 Hz, 1H), 8.36 (dd, J=9 Hz, J=3 Hz, 1H), 8.70 (d, J=3 Hz, 1H), 8.95 (s, 2H); MS (DCl/NH3) m/z 173 (M+H)+., 50998-17-9

The synthetic route of 50998-17-9 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Altenbach, Robert J.; Black, Lawrence A.; Chang, Sou-jen; Cowart, Marlon D.; Faghih, Ramin; Gfesser, Gregory A.; Ku, Yi-yin; Liu, Huaqing; Lukin, Kirill A.; Nersesian, Diana L.; Pu, Yu-ming; Curtis, Michael P.; US2005/256309; (2005); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

50998-17-9, 6-Bromoquinoxaline is a quinoxaline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

50998-17-9, Example 81; 3 -( 1 -Cvano- 1 -memylethy I)-JV- r4-methyl-3 -Cquinoxalin-o-ylaminolphenyllbenzamide; N-(3-Amino-4-methylphenyl)-3-(l-cyano-l-methylethyl)benzamide (Method 60; 0.150 g, 0.51 mmol), 6-bromoquinoxaline (0.109 g, 0.51 mmol), Pd2(dba)3 (0.024 g, 0.026 mmol), BINAP (0.032 g, 0.051 mmol), and sodium fert-butoxide (0.147 g, 1.53 mmol) were combined in toluene (3 ml) in a sealed tube under an argon atmosphere and heated to 100 0C for 15 hours. The reaction mixture was filtered over diatomaceous earth, concentrated and purified by reverse phase preparative HPLC. NMR (300 MHz): 10.24 (s, IH), 8.62 (d, IH), 8.51 (d, IH), 8.31 (s, IH), 7.94 (t, IH), 7.77 – 7.90 (m, 3H), 7.62 – 7.72 (m, IH), 7.48 – 7.58 (m, 2H), 7.45 (dd, 1.98, IH), 7.23 (d, IH), 7.02 (d, IH), 2.16 (s, 3H), 1.67 (s, 6H); m/z 422.

As the paragraph descriping shows that 50998-17-9 is playing an increasingly important role.

Reference£º
Patent; ASTRAZENECA AB; ASTRAZENECA UK LIMITED; WO2006/40568; (2006); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

50998-17-9,With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.50998-17-9,6-Bromoquinoxaline,as a common compound, the synthetic route is as follows.

6-Bromo quinoxaline (2.0 g, 9.5 mmol) in toluene (20 mL) was degassed for 30 min. To this solution, 1-ethoxy vinyl tributyltin (3.8 g, 10.5 mmol) and bis(triphenylphosphine)palladium dichloride (0.67 g, 0.95 mmol) were added at rt and stirred for 16 hours at 90 C. The reaction mixture was cooled to rt and filtered through celite. After evaporation of the solvent, 6 N HCI solution in water (20 mL) was added and the mixture was stirred for 1 hour at rt. It was concentrated and neutralized with sat. NaHCO3. The desired product was extracted with DCM (100 mL), dried over Na2SO4 and concentrated. The crude product was purified by column chromatography to afford the title compound (brown solid). 1H NMR (400 MHz, DMSO-de): delta 9.06-9.04 (m, 2H), 8.70 (d, J=2.4 Hz, 1 H), 8.28 (t, J = 2.8 Hz, 1 H), 8.16 (d, J = 11.6 Hz, 1 H), 2.97 (s, 3H). LCMS: (Method A) 173 (M+H), Rt. 2.25 min, 99.06% (Max).

As the paragraph descriping shows that 50998-17-9 is playing an increasingly important role.

Reference£º
Patent; ASCENEURON S. A.; QUATTROPANI, Anna; KULKARNI, Santosh, S.; GIRI, Awadut Gajendra; (247 pag.)WO2017/144639; (2017); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

50998-17-9,50998-17-9, 6-Bromoquinoxaline is a quinoxaline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Preparation 20: Diethyl-2-(6-quinoxalinyl)-2-butenedioate (P20)The title compound can be prepared through a palladium mediated coupling reaction, using diethyl maleate or fumarate as a common reagent (e.g. Tetrahedron, 2002, 58,6545). For example, a mixture of 6-bromoquinoxaline (1 eq.), diethyl maleate (2.3 eq.), palladium acetate (0.05 eq.), tri(o-tolyl)phosphine (0.1 eq.) and potassium carbonate (2 eq.) in DMF may be warmed to 100 0C and stirred for 16 hours. Quenching with water, extraction with diethyl ether and purification of the crude product by flash chromatography should provide the title compound.

50998-17-9 6-Bromoquinoxaline 610939, aquinoxaline compound, is more and more widely used in various fields.

Reference£º
Patent; GLAXO GROUP LIMITED; WO2007/22933; (2007); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

50998-17-9, 6-Bromoquinoxaline is a quinoxaline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

50998-17-9, (2S,4R)-l-(2-(3-Acetyl-lH-indazol-l-yl)acetyl)-4-fluoro-N-(2-fluoro-3-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)phenyl)pyrrolidine-2-carboxamide (0.158 g), 6- bromoquinoxaline (0.050 g), Pd(dppf)Cl2 (39 mg) and potassium carbonate (0.165 g) were taken in a pressure tube under argon. To this mixture, 4 mL of dioxane and 1 mL of water were added. The mixture was bubbled with argon for 5 min and the vial was stoppered and subjected to microwave irradiation at 100 C for 45 min. The volatiles were removed under reduced pressure and the residue was purified by ISCO (0-2 % MeOH in CH2CI2) to afford compound 83. 1H NMR (400 MHz, DMSO) (major rotamer) delta 2.07- – 2.33 (m, 1H), 2.55-2.72 (m, 1H), 2.61 (s, 3H), 3.95-4.09 (m, 1H), 4.25 (dd, J = 12.5, 21.9 Hz, 1H), 4.79 (t, J = 8.4 Hz, 1H), 5.57 (d, J = 52.8 Hz, 1H), 5.59 (d, J = 17.2 Hz, 1H), 5.80 (d, J = 17.4 Hz, 1H), 7.28-7.49 (m, 4H), 7.69 (d, J = 8.4 Hz, 1H), 7.94 (t, J = 7.6 Hz, 1H), 8.01 (d, J = 8.8 Hz, 1H), 8.14 – 8.21 (m, 3H), 8.99 (d, J = 3.6 Hz, 2H), 10.03 (s, 1H). 19F- MR (DMSO-de ) (major rotamer): delta – 130.1, -175.9.

As the paragraph descriping shows that 50998-17-9 is playing an increasingly important role.

Reference£º
Patent; ACHILLION PHARMACEUTICALS, INC.; WILES, Jason, Allan; PHADKE, Avinash, S.; DESHPANDE, Milind; AGARWAL, Atul; CHEN, Dawei; GADHACHANDA, Venkat, Rao; HASHIMOTO, Akihiro; PAIS, Godwin; WANG, Qiuping; WANG, Xiangzhu; GREENLEE, William; (447 pag.)WO2017/35408; (2017); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.50998-17-9,6-Bromoquinoxaline,as a common compound, the synthetic route is as follows.,50998-17-9

EXAMPLE 1; 6-[3-(Piperidin-l-ylmethvDphenyllquinoxalineA mixture of 6-bromoquinoxaline (42 mg, 0.2 mmol), 3-(piperidin-l-ylmethyl)- phenylboronic acid pinacol ester hydrochloride (67 mg, 0.21 mmol), 2M aqueous sodium carbonate solution (0.3 mL, 0.6 mmol) and Pd(PPh3 )4 (7 mg, 0.006 mmol) in DME (0.6 mL) was heated to 12O0C in a sealed tube, under microwave irradiation, for 20 minutes. After cooling, the mixture was partitioned between saturated ammonium chloride solution and EtOAc (2 mL each), and the organic phase concentrated in vacuo. The residue was purified by preparative HPLC to give the title compound (34 mg, 56%) as a pale yellow- brown gum. deltaH (CDCl3) 8.88 (d, IH), 8.85 (d, IH), 8.33 (d, IH), 8.19 (d, IH), 8.08 (dd, IH), 7.75 (s, IH), 7.68 (d, IH), 7.48 (t, IH), 7.41 (d, IH), 3.69 (s, 2H), 2.46-2.63 (m, 4H), 1.59-1.72 (m, 4H), 1.40-1.53 (m, 2H). LCMS (ES+) 304 (M+H)+, RT 2.49 minutes.

As the paragraph descriping shows that 50998-17-9 is playing an increasingly important role.

Reference£º
Patent; UCB PHARMA S.A.; BUeRLI, Roland; HAUGHAN, Alan, Findlay; MACK, Stephen, Robert; PERRY, Benjamin, Garfield; RAPHY, Gilles; SAVILLE-STONES, Elizabeth, Anne; WO2010/52448; (2010); A2;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider